These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 20331578)

  • 1. The existence of a relationship between increased serum alanine aminotransferase levels detected in premarketing clinical trials and postmarketing published hepatotoxicity case reports.
    Llanos L; Moreu R; Ortin T; Peiró AM; Pascual S; Bellot P; Barquero C; Francés R; Such J; Pérez-Mateo M; Horga JF; Zapater P
    Aliment Pharmacol Ther; 2010 Jun; 31(12):1337-45. PubMed ID: 20331578
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Drug-induced liver injury in hospitalized patients with notably elevated alanine aminotransferase.
    Xu HM; Chen Y; Xu J; Zhou Q
    World J Gastroenterol; 2012 Nov; 18(41):5972-8. PubMed ID: 23139615
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A pre-marketing ALT signal predicts post-marketing liver safety.
    Moylan CA; Suzuki A; Papay JI; Yuen NA; Ames M; Hunt CM
    Regul Toxicol Pharmacol; 2012 Aug; 63(3):433-9. PubMed ID: 22668747
    [TBL] [Abstract][Full Text] [Related]  

  • 4. What are the best reference values for a normal serum alanine transaminase activity (ALT)? Impact on the presumed prevalence of drug induced liver injury (DILI).
    M'Kada H; Munteanu M; Perazzo H; Ngo Y; Ramanujam N; Imbert-Bismut F; Ratziu V; Bonnefont-Rousselot D; Souberbielle B; Schuppe-Koistinen I; Poynard T;
    Regul Toxicol Pharmacol; 2011 Aug; 60(3):290-5. PubMed ID: 21539883
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prevalence and incidence of liver enzyme elevations in a pooled oncology clinical trial cohort.
    Shantakumar S; Landis S; Lawton A; Hunt CM
    Regul Toxicol Pharmacol; 2016 Jun; 77():257-62. PubMed ID: 27025923
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predicting and preventing acute drug-induced liver injury: what's new in 2010?
    Liss G; Rattan S; Lewis JH
    Expert Opin Drug Metab Toxicol; 2010 Sep; 6(9):1047-61. PubMed ID: 20615079
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Art and Science of Diagnosing and Managing Drug-induced Liver Injury in 2015 and Beyond.
    Lewis JH
    Clin Gastroenterol Hepatol; 2015 Nov; 13(12):2173-89.e8. PubMed ID: 26116527
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serum transaminase elevations as indicators of hepatic injury following the administration of drugs.
    Amacher DE
    Regul Toxicol Pharmacol; 1998 Apr; 27(2):119-30. PubMed ID: 9671567
    [TBL] [Abstract][Full Text] [Related]  

  • 9. DILI and drug development: a regulatory perspective.
    Avigan MI
    Semin Liver Dis; 2014 May; 34(2):215-26. PubMed ID: 24879985
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hepatotoxic effects of tacrine administration in patients with Alzheimer's disease.
    Watkins PB; Zimmerman HJ; Knapp MJ; Gracon SI; Lewis KW
    JAMA; 1994 Apr; 271(13):992-8. PubMed ID: 8139084
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enhancing the utility of alanine aminotransferase as a reference standard biomarker for drug-induced liver injury.
    Ozer JS; Chetty R; Kenna G; Palandra J; Zhang Y; Lanevschi A; Koppiker N; Souberbielle BE; Ramaiah SK
    Regul Toxicol Pharmacol; 2010 Apr; 56(3):237-46. PubMed ID: 19903504
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Drug-induced liver injury and drug development: industry perspective.
    Regev A
    Semin Liver Dis; 2014 May; 34(2):227-39. PubMed ID: 24879986
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The current state of serum biomarkers of hepatotoxicity.
    Ozer J; Ratner M; Shaw M; Bailey W; Schomaker S
    Toxicology; 2008 Mar; 245(3):194-205. PubMed ID: 18291570
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Hepatic tolerance of atypical antipsychotic drugs].
    Dumortier G; Cabaret W; Stamatiadis L; Saba G; Benadhira R; Rocamora JF; Aubriot-Delmas B; Glikman J; Januel D
    Encephale; 2002; 28(6 Pt 1):542-51. PubMed ID: 12506267
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The liver and lovastatin.
    Tolman KG
    Am J Cardiol; 2002 Jun; 89(12):1374-80. PubMed ID: 12062731
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Construction and analysis of a human hepatotoxicity database suitable for QSAR modeling using post-market safety data.
    Zhu X; Kruhlak NL
    Toxicology; 2014 Jul; 321():62-72. PubMed ID: 24721472
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Drug-induced liver injury: what was new in 2008?
    Liss G; Lewis JH
    Expert Opin Drug Metab Toxicol; 2009 Aug; 5(8):843-60. PubMed ID: 19505188
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Analysis of the safety evaluation for premarketing clinical trials of hemodialyzer and of postmarketing safety reports of hemodialyzer in Japan and the US: insights into the construction of a sophisticated premarketing evaluation.
    Saito M; Iwasaki K
    J Artif Organs; 2017 Mar; 20(1):62-70. PubMed ID: 27709305
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High lipophilicity and high daily dose of oral medications are associated with significant risk for drug-induced liver injury.
    Chen M; Borlak J; Tong W
    Hepatology; 2013 Jul; 58(1):388-96. PubMed ID: 23258593
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Alanine aminotransferase: a clinical and regulatory tool for detecting liver injury-past, present, and future.
    Senior JR
    Clin Pharmacol Ther; 2012 Sep; 92(3):332-9. PubMed ID: 22871997
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.